-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Aurinia Pharmaceuticals Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2020 to Q2 2024.
- Aurinia Pharmaceuticals Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $756K.
- Aurinia Pharmaceuticals Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $2.25M, a 40.5% increase year-over-year.
- Aurinia Pharmaceuticals Inc. annual Income Tax Expense (Benefit) for 2023 was $551K, a 69.9% decline from 2022.
- Aurinia Pharmaceuticals Inc. annual Income Tax Expense (Benefit) for 2022 was $1.83M, a 141% increase from 2021.
- Aurinia Pharmaceuticals Inc. annual Income Tax Expense (Benefit) for 2021 was $760K.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)